Marc Tessier-Lavigne
Researcher · Founder
Now Founder, Xaira Therapeutics
Latest on AI4S.fyiFunding · Apr 23, 2024 · founderXaira Therapeutics · Round (unnamed) · more than $1 billion in committed capitalPhotos come from each person's X account, their own site, lab or team page, a conference page that lists them as a speaker in the same role, or Wikimedia Commons under the licence credited, so some may be out of date. Anyone can ask for theirs to be replaced or removed. Contact →
Affiliations
Current
- Founder · Xaira Therapeutics
Also named in the companies' announcements: Stanford
Current roles come from these dated records, not from the bio below. Each links the page it was read from.
About
Marc Tessier-Lavigne is chairman and chief executive of Xaira Therapeutics, which he has led since its launch as founding CEO. He was chief scientific officer and executive vice president of research at Genentech, president of The Rockefeller University from 2011 and Stanford's president from 2016, and he still heads a lab in Stanford's biology department. He studied at McGill and at Oxford as a Rhodes Scholar, and took his PhD at University College London.
Read on 2026-09-29; for current roles see Affiliations above. Read at: tessier-lavigne-lab.stanford.edu ↗ · xaira.com ↗ · biospace.com ↗
Founded
Xaira TherapeuticsDrug discovery · 1 round on record · Round (unnamed) more than $1 billion in committed capitalBackground: Former Genentech CSO; former president of Rockefeller and Stanford (founding CEO) (as the company's own announcements put it)
Co-founders: David Baker, Hetu Kamisetty
Nothing else on the record names them yet.
Something wrong or missing on this page? Tell me and it will be fixed or removed. Contact →